Women's Health Deal Benchmarks
Endometriosis, uterine fibroids, menopause, and fertility deal benchmarks. Benchmarks derived from 52 verified transactions.
52
Total Deals
$1.9B
Avg Upfront
6
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
24
license
20
acquisition
4
collaboration
1
option
1
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Sage Therapeutics → Supernus Pharmaceuticals Zurzuvae (zuranolone) acquisition | acquisition | $561M | $795M | Jun 2025 |
Kissei Pharmaceutical → Theramex Linzagolix (YSELTY) | license | $50M | $200M | Dec 2024 |
Dermavant/Roivant → Organon Vtama (tapinarof) acquisition | acquisition | $175M | $1.2B | Sep 2024 |
Organon → Samsung Bioepis endometriosis | license | $200M | $800M | Jul 2024 |
Insilico Medicine → Menarini/Stemline MEN2312 (KAT6A inhibitor) | license | $12M | $500M | Jan 2024 |
ImmunoGen → AbbVie Elahere (mirvetuximab) acquisition | acquisition | $10.1B | $10.1B | Nov 2023 |
Evofem Biosciences → Aditxt Phexxi | acquisition | $25M | $25M | Nov 2023 |
Myovant Sciences → Sumitomo Pharma Myfembree (relugolix combo) | acquisition | $3.0B | $3.0B | Oct 2023 |
Daiichi Sankyo → Merck Patritumab deruxtecan + 2 ADCs (breast) | co development | $4.0B | $22.0B | Oct 2023 |
Sage Therapeutics → Biogen postpartumDepression | collaboration | $875M | $1.5B | Jul 2023 |
Benchmark Your Women's Health Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 52 verified women's health transactions.
Run Women's Health Benchmark